PTC Therapeutics (PTCT) saw its price target boosted to $155 from $135 by Oppenheimer while the firm retained its outperform
May be time for GMCR to rise up
Time to buy
NOW up from here.
CNAT could have news
News, Conferences, Analyst upping targets, CNAT ready to move to $9 - $16
CNAT moves from $6 to $8 quickly
ENDP may miss out on buying BDSI